A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...

Tom Brady's dog is a clone of a "beloved" pet that died, the seven-time Super Bowl champion revealed on Tuesday.

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Meanwhile, ARK sold 15,362 shares of Roku Inc (NASDAQ:ROKU) through its ARKK ETF, totaling $1,668,774. This marks a continuation of ARK’s recent trend of reducing its holdings in the streaming ...

Smith, a microbiologist whose discovery revolutionize the field of genetic engineering, was a Johns Hopkins School of ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...